FDA Must Lift "Limbo" Over Trials In Supplement Development - Congressional Caucus
This article was originally published in The Pink Sheet Daily
Executive Summary
House members say prior clinical studies for ingredients that do not lead to launches of Rx products should not prevent firms from using those same substances for supplements..